Behavioral and psychological symptoms of dementia (BPSD) are challenging to recognize and treat effectively. Despite very effective nonpharmacologic strategies, there are cases where severe BPSD may require biological intervention. The purpose of this review was to clarify safe and evidence-based use of pharmacological agents based on available clinical trial evidence.
Methods
A structured search strategy was used in PubMed, Embase, and Psyclnfo to obtain the most relevant data regarding treatment of BPSD in patients with any-cause dementia.
Results
We screened 1,442 English-language abstracts. Following initial screening, we had 184 unique references to review. A secondary search of these and review articles gave a total of 117 to tabulate and discuss. We categorized the results based on the following classifications: antidepressants, first-generation antipsychotics, second-generation antipsychotics, anticonvulsants/mood stabilizers, sedatives, stimulants, steroid therapies, other medications, other medication strategies, and medication withdrawal.
Conclusions
The judicious use of pharmacotherapy does seem to be appropriate in select cases where behavioral and psychological interventions have been partially effective or where symptoms confer imminent risk of harm.
HebertLEWeuveJScherrPA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology.2013; 80: 1778–1783.
3.
WimoAGuerchetMAliGC. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement.2017; 13: 1–7.
4.
WimoAJönssonLBondJ; Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement.2013; 9: 1-11.e3.
5.
LyketsosCGLopezOJonesB. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA.2002; 288: 1475–1483.
6.
SawaGMZaccaiJMatthewsFE. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry.2009; 194: 212–219.
7.
SelbaekGEngedalKBerghS.The prevalence and course of neuropsychiatric symptoms in nursing home patients with dementia: a systematic review. J Am Med Dir Assoc.2013; 14: 161–169.
8.
GerlachLBKalesHC. Managing behavioral and psychological symptoms of dementia. Psychiatr Clin North Am.2018; 41: 127–139.
9.
GitlinLNKalesHCLyketsosCG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA.2012; 308: 2020-2029.
10.
KalesHCGitlinLNLyketsosCG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ.2015; 350: h369.doi: 10.1136/bmj.h369.
11.
BallardCWaiteJ.The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;CD003476.
12.
BrodatyHArasaratnam C Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry.2012; 169: 946–953.
13.
SchneiderLSTariotPNDagermanKS. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med.2006; 355: 1525–1538.
14.
Cohen-MansfieldJTheinKMarxMS. What are the barriers to performing nonpharmacological interventions for behavioral symptoms in the nursing home?J Am Med Dir Assoc.2012; 13: 400–405.
15.
LiperotiRLandiF.The management of behavioral and psychological symptoms of dementia: the need for tailored interventions. J Am Med Dir Assoc.2013; 14: 306–307.
16.
KalesHCGitlinLNLyketsosCG; Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc.2014; 62: 762–769.
17.
SorbiSHortJErkinjunttiT; EFNS Scientist Panel on Dementia and Cognitive Neurology. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol.2012; 19: 1159–1179.
18.
HortJO'BrienJTGainottiG. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol.2010; 17: 1236–1248.
19.
QaseemASnowVCrossJTJr., . Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med.2008; 148: 370–378.
20.
WaldemarGDuboisBEmreM. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007; 14: e1–e26.
21.
APA Work Group on Alzheimer's Disease and other Dementias; RabinsPV, BlackerD, RovnerBW, . American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry.2007; 164: 5–56.
22.
ReusVIFochtmannLJEylerAE. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia. Am J Psychiatry.2016; 173: 543–546.
23.
BallardCCorbettA.Agitation and aggression in people with Alzheimer's disease. Curr Opin Psychiatry.2013; 26: 252–259.
24.
BallardCGGauthierSCummingsJL. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol.2009; 5: 245–255.
25.
LiuCSRuthirakuhanMChauSA. Pharmacological management of agitation and aggression in alzheimer's disease: a review of current and novel treatments. Curr Alzheimer Res.2016; 13: 1134–1144.
26.
SinkKMHoldenKFYaffeK.Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA.2005; 293: 596–608.
27.
GedaYESchneiderLSGitlinLN. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement.2013; 9: 602–608.
28.
NowrangiMALyketsosCGRosenbergPB. Principles and management of neuropsychiatric symptoms in Alzheimer's dementia. Alzheimers Res Ther.2015; 7: 12.
29.
PollockBGMulsantBHRosenJ. Comparison of Citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002; 159: 460–465.
30.
PollockBGMulsantBHRosenJ. A double-blind comparison of Citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry.2007; 15: 942–952.
31.
CuloSMulsantBHRosenJ. Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord.2010; 24: 360–364.
32.
PorsteinssonAPDryeLTPollockBG. Effect of Citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA.2014; 311: 682–691.
33.
LeonpacherAKPetersMEDryeLT. Effects of Citalopram on neuropsychiatric symptoms in Alzheimer's dementia: evidence from the CitAD study. Am J Psychiatry.2016; 173: 473–480.
34.
BarakYPlopskiITadgerS. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. Int Psychogeriatr.2011; 23: 1515–1519.
35.
ChoeYMKimKWJhooJH. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease. Int J Geriatr Psychiatry.2016; 31: 731–739.
36.
AnHChoiBParkKW. The effect of escitalopram on mood and cognition in depressive Alzheimer's diseasesubjects. J Alzheimers Dis.2017; 55: 727–735.
37.
PetraccaGMChemerinskiEStarksteinSE. A double-blind placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr.2001; 13: 233–240.
38.
LevkovitzYBlochYKaplanD. Fluvoxamine for psychosis in Alzheimer's disease. J Nerv Ment Dis.2001; 189: 126–129.
39.
TakeyoshiKKuritaMNishinoS. Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function. Neuropsychiatr Dis Treat.2016; 12: 641–649.
40.
TeranishiMKuritaMNishinoS. Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. J Clin Psychopharmacol.2013; 33: 600–607.
41.
DeakinJBRahmanSNestorPJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl).2004; 172: 400–408.
42.
LyketsosCGSheppardJMSteeleCD. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry.2000; 157: 1686–1689.
43.
LyketsosCGDelCampoLSteinbergM. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry. 2003; 60: 737–746.
44.
RosenbergPBDryeLTMartinBK. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry.2010; 18: 136–145.
45.
WeintraubDRosenbergPBDryeLT. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry.2010; 18: 332–340.
46.
MagaiCKennedyGCohenCI. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease. Am J Geriatr Psychiatry.2000; 8: 66–74.
47.
LanctôtKL, HerrmannN, Van ReekumR, . Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry.2002; 17: 531–541.
48.
MokhberNAbdollahianESoltanifarA. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry.2014; 47: 131–140.
49.
de Vasconcelos CunhaUG, Lopes RochaF, Avila de MeloR, . A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord.2007; 24: 36–41.
50.
ScoralickFMLouzadaLLQuintasJL. Mirtazapine does not improve sleep disorders in Alzheimer's disease: results from a double-blind, placebo-controlled pilot study. Psychogeriatrics.2017; 17: 89–96.
51.
BanerjeeSHellierJDeweyM. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet.2011; 378: 403–411.
52.
BanerjeeSHellierJRomeoRetal.Study of the use of antidepressants for depression in dementia: the HTA-SADD trial—a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess.2013; 17: 1–166.
53.
RomeoRKnappMHellierJ. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. Br J Psychiatry.2013; 202: 121–128.
54.
TeriLLogsdonRGPeskindE. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology.2000; 55: 1271–1278.
55.
AllainHDautzenbergPHMaurerK. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psychopharmacology (Berl).2000; 148: 361–366.
56.
TariotPNSchneiderLKatzIR. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry.2006; 14: 767–776.
57.
ChanWCLamLCChoyCN. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry.2001; 16: 1156–1162.
58.
SuhGHSonHGJuYS. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry.2004; 12: 509–516.
59.
SuhGHGreenspanAJChoiSK. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry.2006; 21: 654–660.
60.
HuertasDLópez-Ibor AliñoJJ, MolinaJD, . Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study. J Clin Psychiatry.2007; 68: 439–444.
61.
VerheyFRJVerkaaikMLousbergR; Olanzapine-Haloperidol in Dementia Study group. Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial. Dement Geriatr Cogn Disord.2006; 21: 1–8.
62.
GareriPCotroneoALacavaR. Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). Arch Gerontol Geriatr Suppl.2004;207–215.
63.
BrodatyHAmesDSnowdonJ. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry.2003; 64: 134–143.
64.
BrodatyHAmesDSnowdonJ. Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial. Int J Geriatr Psychiatry.2005; 20: 1153–1157.
65.
NaberDGreenspanASchreinerA.Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. Psychopharmacology.2007; 191: 1027–1029.
66.
SultzerDLDavisSMTariotPN. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry.2008; 165: 844–854.
67.
FontaineCSHynanLSKochK. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-relatedbehavioral disturbances in extended care facilities. J Clin Psychiatry.2003; 64: 726–730.
68.
MulsantBHGharabawiGMBossieCA. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry. 2004; 65: 1708–1714.
69.
RainerMHaushoferMPfolzH. Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. Eur Psychiatry.2007; 22: 395–403.
70.
MowlaAPaniA.Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial. J Clin Psychopharmacol.2010; 30: 40–43.
71.
HolmesCWilkinsonDDeanC. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study. Int J Geriatr Psychiatry.2007; 22: 380–381.
72.
StreetJSClarkWSGannonKS; the HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry.2000; 57: 968–976.
73.
ClarkWSStreetJSFeldmanPD. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry.2001; 62: 34–40.
74.
KennedyJSZagarABymasterF. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int J Geriatr Psychiatry.2001, 16(suppll):S24-S32.
75.
MintzerJFaisonWStreetJS. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry.2001, 16(suppll):S71-S77.
76.
CummingsJLStreetJMastermanD. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord.2002; 13: 67–73.
77.
De DeynPP, CarrascoMM, DeberdtW, . Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004; 19: 115–126.
78.
MeehanKMWangHDavidSR. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsycho pharmacology. 2002; 26: 494–504.
79.
DeberdtWGDyskenMWRappaportSA. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry.2005; 13: 722–730.
80.
KurlanRCummingsJRamanR. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology.2007; 68: 1356–1363.
81.
PaleacuDBarakYMireckyI. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study. Int J Geriatr Psychiatry.2008; 23: 393–400.
82.
ZhongKXTariotPNMintzerJ. Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res.2007; 4: 81–93.
83.
BallardCMargallo-LanaMJuszczakE. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ.2005; 330: 874. doi: 10.1136/bmj.38369.459988.8F
84.
HueyEDGarciaCWassermannEM. Stimulant treatment of fro nto temp oral dementia in 8 patients. J Clin Psychiatry.2008; 69: 1981-1982.
85.
De DeynPP, ErikssonH, SvenssonH; Study 115 investigators. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study. Int J Geriatr Psychiatry.2012; 27: 296–304.
86.
De DeynP, JesteDV, SwaninkR, . Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psycho pharmacol.2005; 25: 463–467.
87.
StreimJEPorsteinssonAPBrederCD. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry.2008; 16: 537–550.
88.
MintzerJETuneLEBrederCD. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry.2007; 15: 918–931.
89.
RappaportSAMarcusRNManosG. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc.2009; 10: 21–27.
90.
GrossbergGTKohegyiEMergelV. Efficacy and safety of brexpiprazole for the treatment of agitation in alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry.2019;S1064-7481 (19)30521-4. doi:10.1016/j.jagp.2019.09.009.
91.
TariotPNErbRPodgorskiCA. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry.1998; 155: 54–61.
92.
TariotPNJakimovichLJErbR. Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia. J Clin Psychiatry.1999; 60: 684–689.
93.
OlinJXFoxLS, PawluczykS, . A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry.2001; 9: 400–405.
94.
Leclair-VisonneauLRouaudTDebillyB. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg.2016; 146: 35–39.
95.
HerrmannNLanctôtKLRothenburgLS. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease. Dement Geriatr Cogn Disord.2007; 23: 116–119.
96.
SivalRCHaffmansPMJansenPA. Sodium valproate in the treatment of aggressive behavior in patients with dementia–arandomizedplacebo controlled clinical trial. Int J Geriatr Psychiatry.2002; 17: 579–585.
97.
TariotPNRamanRJakimovichL; Alzheimer's Disease Cooperative Study; Valproate Nursing Home Study Group. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005; 13: 942–949.
98.
TariotPNSchneiderLSCummingsJ; Alzheimer's Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry.2011; 68: 853–861.
99.
CumboELigoriLD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav.2010; 17: 461–466.
100.
HerrmannNLanctôtKLEryavecG. Noradrenergic activity is associated with response to pindolol in aggressive Alzheimer's disease patients. J Psychopharmacol.2004; 18: 215–220.
101.
WangLYShoferJBRohdeK. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry.2009; 17: 744–751.
102.
PeskindERTsuangDWBonnerLT. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study. Alzheimer Dis Assoc Disord.2005; 19: 23–28.
103.
SultzerDLGrayKFGunayI. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry.1997; 5: 60–69.
104.
SultzerDLGrayKFGunayI. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia?J Am Geriatr Soc.2001; 49: 1294–1300.
105.
AsayamaKYamaderaHItoT. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch.2003; 70: 334–341.
106.
SerfatyMKennell-WebbSWarnerJ. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry.2002; 17: 1120–1127.
107.
SingerCTractenbergREKayeJ; Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep.2003; 26: 893–901.
108.
HaffmansPMSivalRCLuciusSA. Bright light therapy and melatonin in motor restless behaviour in dementia: a placebo-controlled study. Int J Geriatr Psychiatry.2001; 16: 106–110.
109.
DowlingGABurrRLVan SomerenEJW, . Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc.2008; 56: 239–246.
110.
Riemersma-van der LekRF, SwaabDF, TwiskJ, . Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA.2008; 299: 2642–2655.
111.
GehrmanPR, ConnorDJ, MartinJL, . Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry.2009; 17: 166–169.
112.
WadeAGFarmerMHarariG. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial. Clin Interv Aging.2014; 9: 947–961.
113.
HerrmannNRothenburgLSBlackSE. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol.2008; 28: 296–301.
114.
PadalaPRPadalaKPLensingSY. Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer's disease: a double-blind, randomized, placebo-controlled trial. Am J Psychiatry.2018; 175: 159–168.
115.
RosenbergPBLanctotKLDryeLT; ADMET Investigators. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry.2013; 74: 810–816.
116.
FrakeyLLSallowaySBuelowM. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease. J Clin Psychiatry.2012; 73: 796–801.
117.
MohsRCShiovitzTMTariotPN. Atomoxetine augmentation of Cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am J Geriatr Psychiatry.2009; 17: 752–759.
118.
WangPNLiaoSQLiuRS. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology.2000; 54: 2061–2066.
119.
KyomenHHHennenJGottliebGL. Estrogen therapy and noncognitive psychiatric signs and symptoms in elderly patients with dementia. Am J Psychiatry.2002; 159: 1225–1227.
120.
HallKAKeksNAO'ConnorDW. Transdermal estrogen patches for aggressive behavior in male patients with dementia: a randomized, controlled trial. Int Psychogeriatr.2005; 17: 165–178.
121.
Valen-SendstadAEngedalKStray-PedersenB. Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. Am J Geriatr Psychiatry.2010; 18: 11–20.
122.
LuPHMastermanDAMulnardR. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol.2006; 63: 177–185.
123.
BowenRLPerryGXiongC. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis.2015; 44: 549–560.
124.
PantoniLdel SerT, SoglianAG, . Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke.2005; 36: 619–624.
125.
CaramelliPLaksJPalminiAL. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). Arq Neuropsiquiatr.2014; 72: 411–417.
126.
CummingsJLLyketsosCGPeskindER. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA.2015; 314: 1242–1254.
127.
FinkelSIMintzerJEDyskenM. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry.2004; 19: 9–18.
128.
MowlaAMosavinasabMHaghshenasH. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol.2007; 27: 484–487.
129.
DyskenMWSanoMAsthanaS. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA.2014; 311: 33–44.
130.
BallardCGThomasAFosseyJ. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry.2004; 65: 114–119.
131.
van ReekumR, ClarkeD, ConnD, . A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr.2002; 14: 197–210.
132.
RuthsSStraandJNygaardHABjorvatnBPallesenS.Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study. J Am Geriatr Soc.2004; 52: 1737–1743.
133.
RuthsSStraandJNygaardHA. Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study–the Bergen District Nursing Home Study (BEDNURS). Int J Geriatr Psychiatry.2008; 23: 889–895.
134.
BallardCLanaMMTheodoulouM. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoSMed.2008; 5: e76.
135.
BallardCHanneyMLTheodoulouM. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol.2009; 8: 151–157.
136.
DevanandDPPeltonGHCunqueiroK. A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int J Geriatr Psychiatry.2011; 26: 937–943.
137.
DevanandDPMintzerJSchultzSK. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med.2012; 367: 1497–1507.
138.
BallardCThomasAGerryS. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). J Am Med Dir Assoc.2015; 16: 316–322.
139.
BerghSSelbaekGEngedalK.Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ.2012; 344: e1566.
140.
CanevelliMAdaliNCantetC. Impact of behavioral subsyndromes on cognitive decline in Alzheimer's disease: data from the ICTUS study. J Neurol.2013; 260: 1859-1865.
141.
CanevelliMAdaliNVoisinT. Behavioral and psychological subsyndromes in Alzheimer's disease using the neuropsychiatric inventory. Int J Geriatr Psychiatry.2013; 28: 795–803.
142.
van der LindeRM, DeningT, MatthewsFE, . Grouping of behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry.2014; 29: 562–568.
143.
Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
144.
OlinJTSchneiderLSKatzIR. Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry.2002; 10: 125–128.
145.
MeyerJPSwetterSKKellnerCH. Electroconvulsive therapy in geriatric psychiatry: a selective review. Psychiatr Clin North Am.2018; 41: 79–93.
146.
DudasRMaloufRMcCleeryJ. Antidepressants for treating depression in dementia. Cochrane Database Syst Rev.2018; 8: CD003944. doi: 10.1002/14651858.CD003944.pub2.
147.
SchererRWDryeLMintzerJ. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. Trials.2018; 19: 46.
148.
RuthirakuhanMTHerrmannNAbrahamEH. Pharmacological interventions for apathy in Alzheimer's disease. Cochrane Database Syst Rev.2018; 5: CD012197. doi:10.1002/14651858.CD012197.pub2.
149.
DaulatzaiMA. Pharmacotherapy and Alzheimer's disease: the M-drugs (melatonin, minocycline, modafinil, and memantine) approach. Curr Pharm Des.2016; 22: 2411–2430.
150.
LyketsosCGCarrilloMCRyanJM. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement.2011; 7: 532–539.
151.
EmreMTsolakiMBonuccelliU. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol.2010; 9: 969–977.
152.
McKeithI Del Ser T, Spano P, . Efficacy of rivas tigmine in dementia with Lewybodies: arandomised, double-blind, placebo-controlled international study. Lancet.2000; 356: 2031-2036.
153.
BurnDEmreMMcKeithI. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord.2006; 21: 1899-1907.
154.
WeintraubDHurtigHI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry.2007; 164: 1491–1498.
155.
SchneiderLSDagermanKSInselP.Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA.2005; 294: 1934-1943.
156.
SuzukiHGenK.Clinical efficacy of lamotrigine and changes in the dosages of concomitantly used psychotropic drugs in Alzheimer's disease with behavioural and psychological symptoms of dementia: a preliminary open-label trial. Psychogeriatrics.2015; 15: 32–37.
157.
TampiRRTampiDJ. Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen.2014; 29: 565–574.
158.
CamargosEFLouzadaLLQuintasJL. Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. Am J Geriatr Psychiatry.2014; 22: 1565–1574.
159.
LebertFStekkeWHasenbroekxC. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord.2004; 17: 355–359.
160.
NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens State Sci Statements. NIH Consens State Sci Statements.2005; 22: 1–30.
161.
BullockLBedsonJJordanJL. Pain assessment and pain treatment for community-dwelling people with dementia: a systematic review and narrative synthesis. Int J Geriatr Psychiatry.2019; 34: 807–821.
162.
HuseboBSBallardCCohen-MansfieldJ. The response of agitated behavior to pain management in persons with dementia. Am J Geriatr Psychiatry.2014; 22: 708–717.
163.
KalesHCLyketsosCGMillerEM. Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. Int Psychogeriatr.2018; 31: 83–90.
164.
KellnerCHHusainMMKnappRG. Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE Study. Am J Psychiatry.2016; 173: 1101–1109.
